
In a renewed push for self-reliance in medicine, the Federal Government of Nigeria has outlined plans to raise local pharmaceutical production to 70 per cent by 2030, signalling a strategic shift to reduce import dependence and strengthen the country’s healthcare industry.
The Minister of State for Health and Social Welfare, Dr Iziak Adekunle Salako, disclosed this during the recent commissioning of a new pharmaceutical manufacturing facility by Sam Pharma in Ota, Ogun State. He described the development as part of a broader national strategy to unlock the healthcare value chain.
Salako said the government’s policy direction is focused on building strong domestic capacity for drug production as a critical pillar of healthcare access, economic development and national security.
According to him, Nigeria’s renewed focus on pharmaceutical manufacturing is driven by lessons from recent global health shocks, particularly the COVID-19 pandemic, which exposed vulnerabilities in global supply chains and triggered what he described as “pharmaceutical nationalism”.
He also pointed to disruptions in global health financing, including shifts in international aid for drug-dependent programmes, which have further underscored the need for domestic resilience.
“The importance of today’s event cannot be overemphasised, especially at this time of our national circumstances and renewed commitment to unlock the healthcare value chain, not just for economic reasons, but as a key enabler of medicine sovereignty,” he said.
“During the COVID-19 pandemic, the world experienced pharmaceutical nationalism, which severely threatened medical security in our country. More recently, we have also faced systemic changes in the global healthcare funding landscape, including restrictions on foreign aid for drug-dependent programmes.
“In the past, factors such as suboptimal prioritisation and a lack of political will prevented the system from harnessing the immense benefits of the pharmaceutical value chain. The Federal Government, under the leadership of President Tinubu, has now positioned the sector not only to meet the healthcare needs of our growing population but also to drive growth in related sectors.”
The minister noted that the government has introduced key interventions to reposition the sector, including the Presidential Initiative to Unlock the Healthcare Value Chain (PVAC) and the Presidential Executive Order for the Pharmaceutical and Allied Sectors.
He explained that PVAC is designed to strengthen coordination across institutions and accelerate value chain transformation, while the Executive Order provides direct incentives for local manufacturing of medicines, syringes, rapid diagnostic test kits and pharmaceutical inputs.
According to him, 87 local manufacturers are already benefiting from the policy, with incentives covering nearly 1,000 harmonised tariff lines, including pharmaceutical machinery, active pharmaceutical ingredients (APIs) and excipients.
Salako said the reforms are already yielding results, citing milestones such as Nigeria’s attainment of World Health Organisation (WHO) prequalification for two pharmaceutical products, the first in West and Central Africa, as well as the establishment of a world-class rapid diagnostic test manufacturing facility in sub-Saharan Africa.
He added that Nigeria is also moving towards the commencement of local active pharmaceutical ingredient production, describing it as a major step towards reducing dependence on imported raw materials.
Dr Salako further disclosed that Nigeria is scaling up production of ready-to-use therapeutic foods to address acute malnutrition among children as part of broader public health interventions.
On research and innovation, he said the Nigerian Institute for Pharmaceutical Research and Development (NIPRD) is establishing an API Capacity Building and Concept Production Centre, with support from Afreximbank, noting that the project is about 85 per cent complete.
He also announced Nigeria’s collaboration with the European Union and other partners under the Manufacturing and Access to Vaccines, Medicines and Health Technologies (MAV+) initiative, an €18 million programme launched in October 2025, to boost local capacity for vaccines, biologics, diagnostics and medical devices.
“Research and development is critical if we are to harness our rich phytomedicinal resources and deploy them effectively to address the health challenges of our people,” he said. “Africa is home to about 25 per cent of the world’s plant genetic resources, many of which have significant potential for drug development.”
He called for increased investment in phytomedicine and urged local manufacturers to collaborate with the government in developing plant-based medicines for mainstream healthcare use.
However, he cautioned that policy incentives must translate into tangible benefits for citizens.
“We must ensure that government waivers and exemptions result in pricing relief for the average Nigerian patient,” he said.
Dr Salako reaffirmed the government’s commitment to sustained reforms through regulatory improvements, tax incentives, investment mobilisation, ease of doing business and strengthened research funding.
He commended the National Agency for Food and Drug Administration and Control (NAFDAC) for maintaining World Health Organisation benchmarking standards and pledged continued support for regulatory strengthening.
He also called on local and international investors to take advantage of the policy momentum to invest in Nigeria’s pharmaceutical sector.
“History shows that Nigeria once played a significant role in global health through its vaccine manufacturing capacity. We must work together to restore that legacy, strengthen our health security, ensure a stable supply of affordable medicines, reduce reliance on imports and improve public health outcomes,” he said.





